Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Abstract Background Monoclonal antibodies (mAbs) directed against tumour necrosis factor alpha (TNF‐α) and interleukin (IL)‐17 and ‐23 represent the ultimate therapeutic strategy in treating psoriasis patients, but scientific literature still does not provide conclusive results regarding the possibl...

Full description

Bibliographic Details
Main Authors: Flavia Manzo Margiotta, Alessandra Michelucci, Salvatore Panduri, Laura Angeloni, Cristian Fidanzi, Giammarco Granieri, Riccardo Morganti, Marco Romanelli, Valentina Dini
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:JEADV Clinical Practice
Subjects:
anti‐interleukin
anti‐TNF‐α
biologic therapy
psoriasis
Online Access:https://doi.org/10.1002/jvc2.236

Internet

https://doi.org/10.1002/jvc2.236

Similar Items